VUNO said it has obtained the Ministry of Food and Drug Safety certification for VUNO Med-LungQuant, an artificial intelligence (AI)-based lung computed tomography (CT) quantification.

The Ministry of Food and Drug Safety has certified VUNO's AI solution that can help diagnose respiratory infectious diseases.
The Ministry of Food and Drug Safety has certified VUNO's AI solution that can help diagnose respiratory infectious diseases.

The solution automatically analyzes lung CT images based on AI to segment characteristic areas in CT images and provides visualization and quantification information for each detailed area. It thus helps healthcare providers determine the type and severity of lung disease.

According to the product's approval, the agreement between the solution and the thoracic radiologist in the lung CT image of the region of interest mark was more than 90 percent, proving high performance. VUNO has developed the source technology for this solution through the Ministry of Science and ICT’s project to foster global companies specializing in software.

As the Covid-19 virus spread in early 2020, physicians discovered abnormal findings such as ground-glass opacity and consolidation in lung CT of infected patients, increasing the need for more CT image-based screening or follow-up observation.

Accordingly, VUNO optimized the original technology developed to precisely analyze and diagnose existing lung diseases to quantify newly emerging infectious diseases. Through this, the company completed the development of the solution by adding detailed analysis and visualization functions for each lung area for faster diagnosis.

Hospitals can use VUNO Med-LungQuant for screening lung diseases precise evaluation of the severity and course of respiratory diseases based on the extent or distribution of lesions.

Also, as the solution can quantify most lung disease patterns, the company expects it to be a useful screening tool for new respiratory infectious diseases in the future.

"The company developed VUNO Med-LungQuant as a part of the national project and obtained certification by proving its clinical effectiveness as an effective tool to assist in the screening and follow-up of respiratory infectious diseases," VUNO CEO Lee Ye-ha said. "The company hopes that the solution will relieve the burden of busy medical staff in more medical fields and contribute to scarce medical resources."

Copyright © KBR Unauthorized reproduction, redistribution prohibited